How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/anemia-due-to-bleeding-uterine-leiomyoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Anemia due to Bleeding Uterine Leiomyoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anemia due to Bleeding Uterine Leiomyoma (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Anemia due to Bleeding Uterine Leiomyoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Lupron	leuprorelin	Accord Healthcare S.L.U.	Gonadotropin Releasing Hormone Receptor Agonist	GnRH receptors	1985-01-01
Lupron	leuprolide	Accord Healthcare S.L.U.	Gonadotropin Releasing Hormone Receptor Agonist	Gonadotropin-releasing hormone receptor	1985-01-01
Leuprolide Acetate	leuprolide-acetate	Pfizer	leuprorelin	Gonadotropin-releasing hormone receptor	1985-01-01
Eligard	Eligard	Astellas Pharma Europe Ltd.		Gonadotropin-releasing hormone receptor, Gonadotropin-releasing hormone receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Accord Healthcare S.L.U. · 2 drugs in Anemia due to Bleeding Uterine Leiomyoma
Astellas Pharma Europe Ltd. · 1 drug in Anemia due to Bleeding Uterine Leiomyoma
Pfizer · 1 drug in Anemia due to Bleeding Uterine Leiomyoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Anemia due to Bleeding Uterine Leiomyoma:

Cite this brief

Drug Landscape (2026). Anemia due to Bleeding Uterine Leiomyoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/anemia-due-to-bleeding-uterine-leiomyoma. Accessed 2026-06-10.

Anemia due to Bleeding Uterine Leiomyoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing